Loading
Life sciences · Journal article
Precision Medical Sciences · September 18, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Precision oncology has initiated a profound paradigm shift in clinical cancer care, replacing historical, empirical treatment models with highly individualized, multi‐omics‐driven therapeutic strategies. However, translating high‐throughput analytical insights into universal bedside execution remains a formidable challenge due to technological fragmentation and systemic bottlenecks. This review comprehensively synthesizes the evolutionary trajectory of genomic, transcriptomic, epigenetic, and spatial multi‐omic diagnostic pipelines. We dissect how the clinical integration of next‐generation sequencing, single‐cell diagnostics, and high‐resolution spatial mapping has refined patient stratification and enabled the deployment of next‐generation modalities, including tumor‐agnostic therapies, antibody‐drug conjugates, and individualized neoantigen mRNA vaccines. Furthermore, we critically evaluate the emergence of functional precision medicine platforms, specifically patient‐derived tumor organoids, for in vitro drug screening alongside real‐time, longitudinal monitoring via liquid biopsies and minimal residual disease tracking. Finally, we examine the pivotal role of artificial intelligence in translating big data into actionable clinical workflows while addressing the regulatory, economic, and accessibility barriers impeding equitable global deployment. Ultimately, this work provides a unified, cross‐disciplinary blueprint to accelerate the transition of precision oncology from data‐rich analytical exploration to definitive clinical execution.